MA57420B1 - Composés anticancéreux - Google Patents

Composés anticancéreux

Info

Publication number
MA57420B1
MA57420B1 MA57420A MA57420A MA57420B1 MA 57420 B1 MA57420 B1 MA 57420B1 MA 57420 A MA57420 A MA 57420A MA 57420 A MA57420 A MA 57420A MA 57420 B1 MA57420 B1 MA 57420B1
Authority
MA
Morocco
Prior art keywords
cancer compounds
cancer
compounds
compound
treatment
Prior art date
Application number
MA57420A
Other languages
English (en)
Inventor
Solloso Andrés Francesch
Marchante Maria Del Carmen Cuevas
Barrasa Valentin Martinez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/EP2018/060868 external-priority patent/WO2018197663A1/fr
Publication of MA57420B1 publication Critical patent/MA57420B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule générale i, dans laquelle r1 à r4 ont diverses significations, et est destiné à être utilisé dans le traitement du cancer.
MA57420A 2017-04-27 2018-04-27 Composés anticancéreux MA57420B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
PCT/EP2018/060868 WO2018197663A1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux

Publications (1)

Publication Number Publication Date
MA57420B1 true MA57420B1 (fr) 2023-06-28

Family

ID=58668823

Family Applications (3)

Application Number Title Priority Date Filing Date
MA58643A MA58643B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux
MA48455A MA48455B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA57420A MA57420B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA58643A MA58643B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux
MA48455A MA48455B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (2)

Country Link
AR (1) AR114387A1 (fr)
MA (3) MA58643B1 (fr)

Also Published As

Publication number Publication date
MA48455A (fr) 2020-03-04
MA58643B1 (fr) 2023-09-27
MA48455B1 (fr) 2023-06-28
AR114387A1 (es) 2020-09-02

Similar Documents

Publication Publication Date Title
MA44021B1 (fr) Composés antitumoraux
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA38039A1 (fr) Composés de céphem substitués en position 2
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
EA201791667A1 (ru) Соединения бензоксаборола и их применение
FR3066761B1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39305A3 (fr) Dérivés d'éthynyle
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA41885A1 (fr) Mélange d'additifs
MA39529A1 (fr) Agent stabilisant hautement efficace
MA57420B1 (fr) Composés anticancéreux
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain